ANXIETY is the #8 most commonly reported adverse reaction for OLANZAPINE PAMOATE, manufactured by H2-Pharma LLC. There are 1,560 FDA adverse event reports linking OLANZAPINE PAMOATE to ANXIETY. This represents approximately 1.8% of all 88,377 adverse event reports for this drug.
OLANZAPINE PAMOATE has an overall safety score of 85 out of 100. Patients taking OLANZAPINE PAMOATE who experience anxiety should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
ANXIETY1,560 of 88,377 reports
ANXIETY is a less commonly reported adverse event for OLANZAPINE PAMOATE, but still significant enough to appear in the safety profile.
Other Side Effects of OLANZAPINE PAMOATE
In addition to anxiety, the following adverse reactions have been reported for OLANZAPINE PAMOATE:
ANXIETY has been reported as an adverse event in 1,560 FDA reports for OLANZAPINE PAMOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is ANXIETY with OLANZAPINE PAMOATE?
ANXIETY accounts for approximately 1.8% of all adverse event reports for OLANZAPINE PAMOATE, making it a notable side effect.
What should I do if I experience ANXIETY while taking OLANZAPINE PAMOATE?
If you experience anxiety while taking OLANZAPINE PAMOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.